Blockchain Registration Transaction Record

Tonix's TONMYA Shows Breakthrough Results in Fibromyalgia Pain & Sleep

Tonix Pharmaceuticals presents Phase 3 data showing TONMYA significantly reduces fibromyalgia pain and improves sleep. First new FDA-approved fibromyalgia treatment in 15+ years.

This development represents a significant advancement in chronic pain management, particularly for the estimated 4 million American adults suffering from fibromyalgia who have had limited treatment options. The approval of TONMYA marks the first new FDA-approved fibromyalgia medication in over 15 years, addressing a critical unmet medical need. Beyond immediate patient impact, this breakthrough demonstrates the viability of non-opioid pain therapeutics at a time when the opioid crisis continues to devastate communities. The treatment's dual action on both pain and sleep disturbance addresses core symptoms that significantly impair quality of life for fibromyalgia patients. For investors, Tonix's diverse pipeline across CNS disorders, immunology, and infectious diseases, including government-funded projects, suggests substantial growth potential in multiple therapeutic areas.